BRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie By: Reuters: Company News April 23, 2014 at 01:44 AM EDT * Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie Read More >> Related Stocks: AbbVie